• If you are wondering whether STERIS is priced fairly at around US$252 per share, you are not alone; many investors are asking whether the current tag matches the underlying business.
• The stock has had a mixed run recently, with a 4% decline over the last week, a 1.8% decline over the last month, but returns of 0.8% year to date, 14.1% over 1 year, 34.6% over 3 years and 44.3% over 5 years.
• Recent news coverage has focused on STERIS as a key player in healthcare equipment and services, which keeps the company on the radar of investors following the sector. This context helps explain why some market participants are reassessing both the risk profile and the potential of the stock at current levels.
• According to Simply Wall St's valuation checks, STERIS currently scores 0 out of 6 for being undervalued. Next, we will look at how different valuation methods treat the stock, before finishing with a more complete way to make sense of that valuation score.

STERIS scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: STERIS Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes the cash STERIS is expected to generate in the future and then discounts those projected cash flows back to today to estimate what the entire business could be worth right now.

For STERIS, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections. The latest twelve month free cash flow is about $870.9 million. Simply Wall St then projects free cash flow forward, including an estimate of $800.01 million for 2025 and a series of annual projections out to 2035, which are extrapolated beyond the typical 5 year analyst horizon.

Rolling all of those discounted cash flows together, the model arrives at an estimated intrinsic value of about $240.61 per share. Compared with the recent share price of roughly $252, this implies the stock is around 4.8% overvalued using this DCF framework, which is a relatively small gap.

Result: ABOUT RIGHT

STERIS is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: STERIS Price vs Earnings

For a profitable company like STERIS, the P/E ratio is a useful way to gauge what investors are currently willing to pay for each dollar of earnings. It ties the share price directly to the business’s ability to generate profit, which is often a key anchor for long term valuations.

What counts as a “normal” P/E depends on how the market views a company’s growth prospects and risk profile. Higher expected growth or lower perceived risk can support a higher multiple, while lower growth or higher risk usually points to a lower one.

STERIS currently trades on a P/E of 34.9x. That sits above the Medical Equipment industry average of 32.8x and the peer group average of 26.1x. Simply Wall St’s Fair Ratio for STERIS is 28.6x, which is a proprietary estimate of what its P/E might be given factors such as earnings growth, profit margins, size, industry and risk. This Fair Ratio can be more informative than a simple comparison with peers or the sector because it adjusts for these company specific traits. Since STERIS’s actual P/E of 34.9x is above the Fair Ratio of 28.6x, the shares screen as overvalued on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 22 top founder-led companies.

Upgrade Your Decision Making: Choose your STERIS Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. With Narratives, you set out a clear story for STERIS and tie it directly to your own assumptions for future revenue, earnings, margins and fair value.

A Narrative on Simply Wall St is your personal storyline for the company that connects what you believe about its products, competitive position and risks to a financial forecast and then to a fair value estimate that you can compare with today’s share price.

These Narratives live in the Community page on Simply Wall St, are easy to set up, and automatically refresh when new information such as news or earnings is added. This means your fair value view for STERIS can adjust in step with the latest data.

That is also how Narratives can support your decision on whether it might be time to buy, hold or sell. You can see at a glance whether your Fair Value is above or below the current market price, and how other investors’ STERIS Narratives span from very cautious fair values to very optimistic ones.

Do you think there's more to the story for STERIS? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.